Rigel Pharmaceuticals to report Q3 2026 results and provide business update on November 5

Rigel Pharmaceuticals to report Q3 2026 results and provide business update on November 5
Rigel Q3 2026 earnings set

Rigel Pharmaceuticals announced it will release its third quarter 2026 financial results and provide a business update on November 5. The company shared the date in a statement and directed stakeholders to its website for further details.

No additional specifics about the upcoming financial report or business update were disclosed in the announcement.

Rigel recently announced plans to present new data on pralsetinib in RET fusion-positive tumors and lung cancer at the ESMO Congress 2026. The company has focused on expanding its oncology pipeline in recent updates. No further details about the upcoming financial results have been provided.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.